Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study

Autoři

KAYSER S. HILLS R. K. LANGOVA R. KRAMER M. GUIJARRO F. ŠUSTKOVÁ Zuzana ESTEY E. H. SHAW C. M. RÁČIL Zdeněk MAYER Jiří ZAK Pavel BAER M. R. BRUNNER A. M. SZOTKOWSKI T. CETKOVSKY Petr GRIMWADE D. WALTER R. B. BURNETT A. K. HO A. D. EHNINGER G. MULLER-TIDOW C. PLATZBECKER U. THIEDE C. ROLLIG C. SCHULZ A. WARSOW G. BRORS B. ESTEVE J. RUSSELL N. H. SCHLENK R. F. LEVIS M. J.

Rok publikování 2021
Druh Článek v odborném periodiku
Časopis / Zdroj British journal of haematology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.17336
Doi http://dx.doi.org/10.1111/bjh.17336
Klíčová slova acute myeloid leukaemia; t(8;16)(p11;p13)/MYST3-CREBBP; whole-genome sequencing; allogeneic haematopoietic cell transplantation; outcome
Popis In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3-CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16-75) years. AML was de novo in 58%, therapy-related (t-AML) in 37% and secondary after myelodysplastic syndrome (s-AML) in 5%. Cytogenetics revealed a complex karyotype in 43%. Besides MYST3-CREBBP, whole-genome sequencing on a subset of 10 patients revealed recurrent mutations in ASXL1, BRD3, FLT3, MLH1, POLG, TP53, SAMD4B (n = 3, each), EYS, KRTAP9-1 SPTBN5 (n = 4, each), RUNX1 and TET2 (n = 2, each). Complete remission after intensive chemotherapy was achieved in 84%. Median follow-up was 5 center dot 48 years; five-year survival rate was 17%. Patients with s-/t-AML (P = 0 center dot 01) and those with complex karyotype (P = 0 center dot 04) had an inferior prognosis. Allogeneic haematopoietic cell transplantation (allo-HCT) was performed in 21 (36%) patients, including 15 in first complete remission (CR1). Allo-HCT in CR1 significantly improved survival (P = 0 center dot 04); multivariable analysis revealed that allo-HCT in CR1 was effective in de novo AML but not in patients with s-AML/t-AML and less in patients exhibiting a complex karyotype. In summary, outcomes of patients with t(8;16) are dismal with chemotherapy, and may be substantially improved with allo-HCT performed in CR1.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info